Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,069 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammation Clear all
Withdrawn No phase listed Observational

Muscle Atrophy in Sepsis

NCT00583206
View directory record Official record
Conditions
Atrophy, Sepsis, Weakness
Interventions
Not listed
Lead sponsor
Gregory A. Schmidt
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 4 Interventional

DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

NCT04462523
View directory record Official record
Conditions
Vitreo-Retinal Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Patrick R. Oellers, MD
Network
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 20, 2026, 6:40 PM EDT
Not listed Not applicable Interventional

Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens

NCT02764359
View directory record Official record
Conditions
Infection, Sepsis, Obesity
Interventions
IV vancomycin
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 99 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Moderate to Severe Refractory Crohn's Disease

NCT06721962
View directory record Official record
Conditions
Crohns Disease
Interventions
TRX103, Cyclophosphamide
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bladder Morphology Using 2 Different Catheter Designs

NCT03108079
View directory record Official record
Conditions
Urologic Injuries, Urologic Diseases, Bladder Infection, Urinary Tract Infections, Mucosal Inflammation, Mucosal Infection, Bladder Injury, Catheter-Related Infections, Catheter Complications, Catheter; Infection (Indwelling Catheter), Pelvic Floor Disorders, Urinary Incontinence
Interventions
Cystosure Urinary Access System, Foley Catheter
Device
Lead sponsor
The Pelvic Floor Institute
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

Xanthohumol Metabolism and Signature

NCT03735420
View directory record Official record
Conditions
Healthy
Interventions
Xanthohumol, Placebo oral capsule
Drug
Lead sponsor
National University of Natural Medicine
Other
Eligibility
21 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting Not applicable Interventional

Trans-Auricular Stimulation for Postoperative Inflammation in Spine Surgery

NCT07218133
View directory record Official record
Conditions
Spinal Fusion, Hyperglycemia, Postoperative Pain Management, Postoperative Care, Spine Disease, Neurologic Deficits, Neurological Disorder, Inflammation, Spine Condition, Spinal (Fusion) Surgery, Cytokine Levels, Spine Fusion
Interventions
Auricular vagus nerve stimulation, Sham Auricular Vagus nerve Stimulation
Device
Lead sponsor
Alexander T. Yahanda
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

NCT01751152
View directory record Official record
Conditions
Inflammation, Crohn's Disease
Interventions
NNC0114-0006, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
9
States / cities
Tucson, Arizona • Little Rock, Arkansas • Laguna Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Jul 20, 2026, 6:40 PM EDT
Not listed Phase 3 Interventional

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

NCT04433949
View directory record Official record
Conditions
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Low Dose Radiation Therapy
Other · Radiation
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Grape Seed Extract and Postprandial Oxidation and Inflammation

NCT01190358
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Placebo, Grape seed extract
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Davis, California • Mather, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Jul 20, 2026, 6:40 PM EDT
Not listed No phase listed Observational

Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)

NCT01074515
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
4
States / cities
San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Jul 20, 2026, 6:40 PM EDT
Not listed No phase listed Observational

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

NCT06126263
View directory record Official record
Conditions
Streptococcal Sepsis, Invasive Group A Beta-Haemolytic Streptococcal Disease, Necrotizing Soft Tissue Infection, Infection, Bloodstream, Infection, Bacterial, Streptococcal Toxic Shock Syndrome
Interventions
Linezolid, Clindamycin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jul 20, 2026, 6:40 PM EDT
Completed No phase listed Observational

Evaluation of the Heparin Binding Protein Levels in Sepsis

NCT02533011
View directory record Official record
Conditions
Sepsis, Infection, Septic Shock
Interventions
HBP lab test
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
1,055 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Jul 20, 2026, 6:40 PM EDT
Completed No phase listed Observational

Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock

NCT01867905
View directory record Official record
Conditions
Severe Sepsis, Septic Shock, Bacteremia
Interventions
Not listed
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

NCT03604705
View directory record Official record
Conditions
Candidemia
Interventions
APX001
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672
View directory record Official record
Conditions
ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Mucocutaneous Ulcer, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Large B-Cell Lymphoma With 11q Aberration, Large B-Cell Lymphoma With IRF4 Rearrangement, Plasmablastic Lymphoma, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Effusion Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Lymphomatoid Granulomatosis, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Gray-Zone Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Nivolumab, Varlilumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Maqui Berry Extract and Omega-3 Fatty Acids for Cytokine Reduction

NCT04914312
View directory record Official record
Conditions
Inflammation
Interventions
Maqui berry/omeg-3 fatty acids, Placebos
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
50 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Jul 20, 2026, 6:40 PM EDT
Not listed Phase 2 Interventional

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

NCT01202812
View directory record Official record
Conditions
Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions
Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules
Dietary Supplement · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 19 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2010 · Synced Jul 20, 2026, 6:40 PM EDT
Not yet recruiting Not applicable Interventional

Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress

NCT07634419
View directory record Official record
Conditions
Critical Illness, Heart Failure, Sepsis, Ards, Pneumonia, Trauma Injury
Interventions
Lift mobile mindfulness, Enlighten Recovery education program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

NCT01576003
View directory record Official record
Conditions
Bloodstream Infections, Short Bowel Syndrome, Development, Nutrition, Biological Markers
Interventions
Glutamine, L-alanine
Drug · Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Weeks to 12 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Inflammation and Daily Life Study

NCT03771612
View directory record Official record
Conditions
Inflammation
Interventions
Naproxen, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 60 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Jul 20, 2026, 6:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Obesity and Adipose Tissue Inflammation in Pregnant Mothers

NCT03412981
View directory record Official record
Conditions
Healthy
Interventions
pregnant mothers
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

Effects of Endotoxin in Normal Human Volunteers

NCT00001303
View directory record Official record
Conditions
Healthy, Lung Disease, Sepsis, Septic Shock
Interventions
Reference Endotoxin, Inhaled Nitric Oxide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 45 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Jul 20, 2026, 6:40 PM EDT
Recruiting Phase 4 Interventional

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

NCT06569212
View directory record Official record
Conditions
Non-Traumatic Subarachnoid Hemorrhage
Interventions
Metoprolol, Placebo
Drug
Lead sponsor
Madeleine Puissant
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jul 20, 2026, 6:40 PM EDT